anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Numerous diseases-related acute lung injury (ALI) contributed to high mortality. Currently, the therapeutic effect of ALI was still poor. The detailed mechanism of ALI remained elusive and this study aimed to elucidate the mechanism of ALI.
METHOD: This study was performed to expose the molecular mechanisms of AMPK/Nrf2 pathway regulating oxidative stress in LPS-induced AMI mice. The mouse ALI model was established via intraperitoneal injection of LPS, then the lung tissue and blood samples were obtained, followed by injection with Dimethyl fumarate (DMF). Finally, Western blot, HE staining, injury score, lung wet/dry ratio, reactive oxygen species (ROS) and ELISA were used to elucidate the mechanism of AMPK/Nrf2 pathway in LPS -induced acute lung injury by mediating oxidative stress.
RESULTS: The lung tissue injury score was evaluated, showing higher scores in the model group compared to the AMPK activator and control groups. DCFH-DA indicated that LPS increased ROS production, while AMPK activator DMF reduced it, with the model group exhibiting higher ROS levels than the control and AMPK activator groups. The lung wet/dry ratio was also higher in the model group. Western blot analysis revealed LPS reduced AMPK and Nrf2 protein levels, but DMF reversed this effect. ELISA results showed elevated IL-6 and IL-1β levels in the model group compared to the AMPK activator and control groups.
CONCLUSION: CONCLUSION: Activating the AMPK/Nrf2 pathway can improve LPS-induced acute lung injury by down-regulation of the oxidative stress and corresponding inflammatory factor level.
Disclosed is a pharmaceutical composition for release control comprising a plurality of particles for release control. The plurality of particles for release control comprise a core material containing methylphenidate and a polymer coating layer for release control formed on the core material. The plurality of particles for release control are divided into two or more groups based on the average thickness of the polymer coating layer for release control. The particle groups are identical in terms of the composition of the polymer in the polymer coating layer, but are different in terms of the average thickness of the coated layer. The pharmaceutical composition for release control according to the present invention may control the relase pattern of methylphenidate contained in the core material as desired, and can be used as an oral formulation in a variety of forms such as orally disintegrating tablets, etc. 41
The 20-minute horse-assisted intervention takes place in compliance with basic safety precautions (safety bar between horse and participant) and after safety instruction in handling the therapy horse. The horse can be touched or stroked more or less intensively, depending on the needs and current state of mind of the study participant.
The present invention relates to a health care food with notoginseng and ginkgo leaf and a preparation method thereof. The health care food with notoginseng and ginkgo leaf is composed of a conjunct extractive of notoginseng and chrysanthemum, an extractive of ginkgo leaf, and medicinal supplementary materials, the medicinal supplementary materials are dextrin and powdered sugar or starch. When prepared into granules, the components has the following weight percentages: 5 to 40% of thick paste of conjunct extractive of notoginseng and chrysanthemum, 0.1 to 10% of an extractive of ginkgo leaf, 4 to 6% of dextrin and 44 to 90% of powdered sugar. When prepared into capsules, the components has the following weight percentages: 40 to 80% of dry power of a conjunct extractive of notoginseng and chrysanthemum, 8 to 20% of an extractive of ginkgo leaf and 0.1 to 52% of starch. The health care food comprises effective components of 1 to 80% notoginseng saponin and 0.1 to 30% of ginkgetin. The health care food of the present invention is prepared by extracting and merging effective components in notoginseng, gingko and chrysanthemum, has the functions of resisting oxidation, raising immunizing power, improving microcirculation, and is favourable for the health of the angiocarpy and the cerebral blood vessel. The health care food can be prepared into tea with notoginseng and gingko, and line products, has scientific and reasonable preparation method, and effectively reserves effective active components in notoginseng, chrysanthemum and ginkgo leaf.
Transcatheter aortic valve replacement (TAVR) using the Edwards SAPIEN valve and Retroflex 3 delivery system provides both a mortality and quality of life benefit for inoperable patients. Only the transfemoral (TF) access has been approved in the US. A substantial number of patients cannot have a TF approach due to inadequate vessel size, vessel disease, or other anatomical considerations. The pivotal study did not include an assessment of safety and effectiveness of alternative access approaches in this inoperable patient group.

Early approaches to TAVR included a femoral transvenous approach with transseptal access to the left side for delivery of the valve. This approach avoided large bore arterial catheterization, but it had unacceptable rates of complications and lacked reproducibility. Alternative access approaches have been developed because of the risks associated with inserting large caliber catheters into small, diseased femoral arteries often associated with diffuse vasculopathy. To avoid the vascular complications from femoral access, other transcatheter approaches have been developed to include open surgical access to the left ventricular apex (TA), ascending aorta, (TAO), subclavian and axillary arteries (TS), and retroperitoneal access to the iliac artery (TI) as well as distal aorta. In addition to providing TAVR to patients who cannot have TF access, additional advantages include better catheter control and safer closure of the access site. Commonly cited disadvantages include the need for surgical expertise and additional equipment, along with the potential for longer recovery, more incisional pain, greater radiation exposure for operators, unsuitable delivery catheters for alternative access sites, and a host of unique alternative access site complications.

We propose to collectively analyze 30-day safety endpoints as a lumped data group for these alternative access approaches. These data are gathered from clinical practice in real-world settings and submitted to the TVT Registry. It is expected that centers will choose among the various choices for alternative access based the causative factors underlying the need for alternative access, as well as local skill sets and experience. For this lumped data group of alternative access approaches we will compare 30-day safety results to the TA outcomes reported from Cohort A of the PARTNERS 1 trial. We recognize that these TA patients were high risk operable patients rather than inoperable patients, but no other direct comparator group is available. We reason that the TA data from this published clinical trial are high quality, represent an alternative access approach rather than TF, and will provide a frequency of safety endpoints that have been found to be acceptable both clinically and from a regulatory perspective.
The Program SI! is a multilevel school-based intervention integrating four cardiovascular health-related components (diet, physical activity, human body and emotions management). Since the Program SI! for preschoolers has shown good results in improving healthy lifestyle habits in children aged 3 to 5 years, the investigators have developed the Program SI! for Elementary addressed to children from 6 to 11 years. The objective of the study is to evaluate the effects of Program SI! for Elementary in different times of exposure for childrens and their immediate environment (teachers, parents and school). In the Community of Madrid-South Area (Spain), 48 public schools from were randomly assigned to Program SI! for Elementary during 3 or 6 academic years (intervention group) or keep their normal curriculum (control group). The main outcome is 3-year, and 6-year changes from baseline of questionnaire scoring of children, and the secondary outcome is 3-year, and 6-year changes from baseline of questionnaire scoring of their parents and teachers in regards to a healthy lifestyle, as well as changes in the school environment. For children were included 3-year, and 6-year changes of cardiovascular markers derived from blood pressure and anthropometry (weight, height, waist circumference and skinfold thickness). The Program SI! for Elementary is designed for different exposures in a sample of schools never intervened to asses when the intervention has the most effectiveness. Besides, as some schools involved in the preschool study continues the Program SI! for Elementary, the investigators can be able to evaluate the impact of the Program SI! in different school stages, concluding how children keep the adoption of healthy behaviors from early in life.
For the group of participants who will be randomized to concomitant CO2 insufflation; the Veress will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by starting the CO2 gas insufflation and insertion of the Veress needle. If the opening pressure is less than or equal to 10 mmHg, the process of insufflation will be allowed to continue. In case of a higher opening pressure, the veress will be withdrawn and reinserted up to 3 times. A failed entry will be called if the peritoneal cavity cannot be insufflated after 3 attempts.
A single or multiple drug overdose with this combination product is a potentially lethal polydrug overdose, and consultation with a regional poison control center is recommended. Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption. 

Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Assisted or controlled ventilation should also be considered.

Gastric decontamination with activated charcoal should be administered just prior to N-acetylcysteine (NAC) to decrease systemic absorption if acetaminophen ingestion is known or suspected to have occurred within a few hours of presentation. Serum acetaminophen levels should be obtained immediately if the patient presents 4 hours or more after ingestion to assess potential risk of hepatotoxicity; acetaminophen levels drawn less than 4 hours post-ingestion may be misleading. To obtain the best possible outcome, NAC should be administered as soon as possible where impending or evolving liver injury is suspected. Intravenous NAC may be administered when circumstances preclude oral administration.

Vigorous supportive therapy is required in severe intoxication. Procedures to limit the continuing absorption of the drug must be readily performed since the hepatic injury is dose dependent and occurs early in the course of intoxication.
A computer implemented health record system and method for maintaining, providing and updating user health records. The system provides smart cards to users on registration, which are associated with the users' health records and have a unique identification number corresponding to every user. The system stores users' information along with their health records and demographic information and associates it with their unique identification number. The demographic information can be edited/ updated by a user on successful authentication. When a registered user visits a health facility/ laboratory, after successful second level authentication, a health physician/ doctor is able to access the user's records and medical history along with user's demographic information in order to provide a better treatment. Any treatment details after the diagnosis and/or prescription provided by the health physician and the test results from the laboratory are then uploaded though a network and maintained by the system. 112 114 116 120 128 122 124& 12 6
Compositions including anti-viral compositions, therapeutic compositions, sunscreen compositions, skin treatment compositions, anti-aging compositions, and methods of making the same, are provided. Each composition includes milk fat globules (MFG) and may contain one or more agents encapsulated by the MFG. The unique nature of MFG provides an intact mammalian membrane containing proteins, glycoproteins, and carbohydrates found in mammary cells. By treating an infected patient with MFG, the MFG serve as a surrogate cell and interact with enveloped viruses, such as the COVID-19 coronavirus, the Herpes virus, and the Epstein Barr Virus, rendering them non-infectious. MFG derived from mammals can also be used to deliver pharmaceutical materials into an animal body such that the pharmaceutical materials bypass the venous blood and enter directly into the animal's lymphatic system. MFG allow the delivery of materials orally that could not heretofore have been delivered efficiently.
FIELD: medicine. ^ SUBSTANCE: in order to obtain gel used is platelet-rich plasma, which is prepared by centrifugation of autoblood in centrifuge with vertical axis of rotation. Autoblood is placed into cylindrical cup of centrifuge, which has pocket-trap. In process of centrifugation turbulence of autoblood and its separation into components with their separate simultaneous accumulation: erythrocytes - on cup bottom, and rich and poor in platelets plasma - in pocket-trap. Centrifugation is performed at rate, reducing each three minutes, whose value is selected successively from the following ranges, rot/min.: 4500-3500, 2500-1500, 1200-800. ^ EFFECT: method makes it possible to increase treatment quality and reduce its terms due to gel base quality - in fact admixture-free plasma, rich with viable platelets, containing great number of growth factors. ^ 6 cl, 4 dwg
A digit protection assembly includes an outer shell that includes a moisture repellant material. A strap is operably coupled to the outer shell. The strap includes a fastener that is operably coupled to an attachment end of the strap. An inner liner is operably coupled to the outer shell and defines a pocket between the inner liner and the outer shell. The inner liner includes an absorbent material. A medication is disposed on the inner liner. The medication comprises cannabidiol oil.
Participants wear sham wristwatch devices but without vibration cueing, 3 consecutive hours daily, for 4 weeks, as well as usual care during the intervention period. They are also encouraged to use their arms as much as possible and the accelerometer built-in the device record the arm movement during daily activities.
Therapy resistance represents a significant challenge in oncology, occurring in various therapeutic approaches. Recently, animal models and an increasing set of clinical trials highlight the crucial impact of the gut and tumor microbiome on treatment response. The intestinal microbiome contributes to cancer initiation, progression, and formation of distant metastasis. In addition, tumor-associated microbiota is considered a critical player in influencing tumor microenvironments and regulating local immune processes. Intriguingly, numerous studies have successfully identified pathogens within the gut and tumor microbiome that might be linked to a poor response to different therapeutic modalities. The unfavorable microbial composition with the presence of specific microbes participates in cancer resistance and progression via several mechanisms, including upregulation of oncogenic pathways, macrophage polarization reprogramming, metabolism of chemotherapeutic compounds, autophagy pathway modulation, enhanced DNA damage repair, inactivation of a proapoptotic cascade, and bacterial secretion of extracellular vesicles, promoting the processes in the metastatic cascade. Targeted elimination of specific intratumoral bacteria appears to enhance treatment response. However, broad-spectrum antibiotic pretreatment is mostly connected to reduced efficacy due to gut dysbiosis and lower diversity. Mounting evidence supports the potential of microbiota modulation by probiotics and fecal microbiota transplantation to improve intestinal dysbiosis and increase microbial diversity, leading to enhanced treatment efficacy while mitigating adverse effects. In this context, further research concerning the identification of clinically relevant microbiome signatures followed by microbiota-targeted strategies presents a promising approach to overcoming immunotherapy and chemotherapy resistance in refractory patients, improving their outcomes.
Prescription opioids, particularly for treating musculoskeletal pain, are a significant contributor to the opioid epidemic in North America. There is also evidence to suggest that chronic use of opioids is associated with poor outcomes after orthopedic surgery. However, whether this association is relevant in foot and ankle surgery is still unclear. Accordingly, a systematic review of the literature was undertaken to assess the impact of preoperative opioid use in patients undergoing foot and ankle surgery concerning postoperative pain, complications, and postoperative opioid dependence. Four databases, including EMBASE, MEDLINE, PubMed, and CINAHL, were searched to March 2022 for studies reporting preoperative opioid use and its effect on postoperative outcomes or opioid use after foot and ankle surgery. A total of 22,092 patients were included in the final synthesis of 8 studies. Most of which were level 3 evidence (5 studies). Around 18% of the patients used opioids preoperatively. Preoperative opioid use was associated with more quantities and prolonged use of opioids postoperatively. Two studies showed an increased risk of complications postoperatively in patients who used opioids preoperatively compared to the nonopioid group. Preoperative opioid use in patients undergoing foot and ankle surgeries is associated with increased and prolonged use of opioids postoperatively and may therefore predict the potential for misuse.
Blood pressure responses during dynamic exercise will be assessed. The intervention is to provide subjects with either a low sodium meal (138 mg sodium) and high sodium meal (1,495 mg sodium), in a randomized order. Blood pressure reactivity during dynamic exercise will be assessed after soup consumption.
The initial starting dose of imatinib mesylate was 400 mg by mouth once daily but intra-patient dose escalation for patients who did not achieve complete response (CR) was built in upon restaging at weeks 8 and 16. At week 8, patients with partial response (PR) or stable disease (SD) were dose escalated to 600 mg. At week 16, if these patients continued in PR or SD, dose escalated to 800 mg and for patients on 400 mg dose escalated to 600 mg. Patients who experienced disease progression could be dose escalated per MD discretion. Patients were treated as long as receiving clinical benefit and no unacceptable toxicity.
Provided herein are placental extracellular matrix (ECM) compositions and methods of making the same. Also provided herein are uses of the placental ECM compositions provided herein. In one aspect, provided herein are extracellular matrix (ECM) compositions prepared using placental tissue, e.g., human placental tissue. In certain embodiments, the ECM compositions provided herein comprise about 30% to about 60% collagen and about 10% to about 35% elastin. In addition, such ECM compositions comprise (i) very low amounts of fibronectin (e.g., less than 0.1% fibronectin), e.g., as measured by ELISA; (ii) no or an undetectable amount of laminin, e.g., as measured by ELISA; and/or no or an undetectable amount of glycosaminoglycans, e.g., as measured by ELISA. In a specific embodiment the placental ECM composition comprises 35-55% collagen by dry weight and 10-30% elastin by dry weight. In a further embodiment the placental ECM composition comprises 40-70% collagen by dry weight and 15-25% elastin by dry weight.
PF-06817024 is a high affinity, humanized antibody that binds interleukin-33, a proinflammatory type 2 cytokine, and thereby has the potential to inhibit downstream type 2 inflammation. This Phase 1, randomized, placebo-controlled study was conducted in 3 parts to evaluate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and pharmacodynamics of escalating single and limited repeat PF-06817024 doses in healthy participants (Part 1), a single dose of PF-06817024 in participants with chronic rhinosinusitis with nasal polyps (Part 2), and repeat doses of PF-06817024 in participants with moderate to severe atopic dermatitis (atoptic dermatitis; Part 3). PF-06817024 was generally well tolerated in all participant populations. Most participants experienced a treatment-emergent adverse event (healthy participants, 78.4% and 100%; participants with chronic rhinosinusitis with nasal polyps, 90.9% and 88.9%; and participants with atoptic dermatitis, 60.0% and 62.5% in the PF-06817024 and placebo groups, respectively). No substantial deviations from dose proportionality were observed for single intravenous doses of 10-1000 mg, indicating linear PK in healthy participants. Mean terminal half-life ranged from 83 to 94 days after single intravenous administration in healthy participants and was similar to that observed after administration in the studied patient populations. Incidences of antidrug antibodies in the studied populations were 10.8%, 9.1%, and 5.0% for healthy participants, participants with chronic rhinosinusitis with nasal polyps, and participants with atoptic dermatitis, respectively. In addition, dose-dependent increases were observed in total serum interleukin-33 levels of treated participants, indicating target engagement. Overall, the PK and safety profile of PF-06817024 supports further investigation of the drug as a potential treatment for allergic diseases.
Subjects to consume 4-ounces of salt water at 9:00 am before breakfast and 4-ounces of salt water at 10:15 pm prior to bedtime. 24-h resting energy expenditure and RQ to be measured.
FIELD: biotechnology, veterinary science. SUBSTANCE: vaccine has antigens of P. multicida, serological variant A - strain DEP-8683, serological variant B - strain DEP-B681, serological variant D - strain DEP-T80 inactivated with formalin and adjuvant consisting of mineral oil and lanolin. Concentration of each strain in vaccine is (3.0 x 10)-(4.8 x 10) microbe cells/cm. Vaccine is administrated by intramuscularly to swine dams independently of age 4-5 weeks before farrowing at dose 5.0 cm, to piglets - twice before 60 days age at dose 2.0 cmand at the age above 60 days - at dose 3.0 cm. Vaccine shows prophylaxis effect with regard to hemosepticemia of pasteurellosis etiology, decreases pneumoniae by 50-80%, promotes the gain in weight by 20-30 g/day. Vaccine provides the prolonged and expressing immunity for pasteurellosis control in pigs caused by P. multicida, serovariants A, B and D. EFFECT: enhanced effectiveness.
The investigators will use a participatory approach to develop and test the feasibility and acceptability of CTHS in community health center sites in Contra Costa County. Development of the program will be informed by active engagement with a patient advisory group composed of current smokers and clinical team members who serve current smokers in community health centers. Feasibility and acceptability will be assessed by implementing the CTHS program for patients in 3 clinical sites, using the RE-AIM evaluation framework. Primary outcomes will include the number and proportion of enrolled smokers who create at least one health-related action plan with a health educator, and stated intention of clinical teams to continue using CTHS after the research. The investigators will enroll 90 smokers in CTHS and 90 additional smokers in Enhanced Standard of Care (ESC) which will be the active comparison group. Participants will be randomly assigned. Smoking status will be reassessed after 3 months. Primary outcomes will include number of 24-hour quit attempts, and 7-day smoking abstinence, as well as changes in self-efficacy and readiness to quit smoking among participants who do not quit. Results of this pilot program will inform further development of the CTHS program for testing in larger scale clinical trials.